Omariglip 12.5: Each film-coated tablet contains Omarigliptin 12.5 mg

Omariglip 25: Each film-coated tablet contains Omarigliptin 25 mg

INN

Antidiabetic

Omarigliptin is an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes

Omarigliptin is contraindicated in patients with known hypersensitivity to any of its components. Moreover, it is also contraindicated to Severe ketosis, diabetic coma or precoma in type-1 diabetes patients.

The usual recommended dose of Omarigliptin is 25 mg once weekly as monotherapy or as add-on therapy for optimization of glycemic control. The dosage should be reduced to 12.5mg once weekly in patient’s with severe renal dysfunction and in patients with end-stage renal failure or in those requiring hemodialysis or peritoneal dialysis according to the following table:

*: Conversion value corresponding to the eGFR (60 years of age)

Hypoglycemia, acute pancreatitis and intestinal obstruction. Other side effects are: Gastrointestinal problem, constipation, diarrhea, skin and subcutaneous tissue disorders.

Since this drug is mainly excreted by the kidneys therefore dose should be titrated in patients with severe renal impairment, hemodialysis or peritoneal dialysis and end-stage renal failure.

Other anti-diabetic drugs (in particular, insulin preparation or sulfonylurea) should be used with caution in combination with Omarigliptin, as they may cause hypoglycemia.

Following patients or conditions which might cause low blood sugar:

1. Pituitary dysfunction or adrenal insufficiency

2. Malnutrition, starvation, irregular dietary intake, lack of dietary intake or debilitated state

3. Excessive alcohol intake

4. The elderly

Blood glucose level should be carefully monitored when using drugs that attenuate the hypoglycemic action such as β blocker, salicylic acid, monoamine oxidase inhibitors, (adrenaline, adrenocorticotropic hormone, thyroid hormone, etc.).

Omarigliptin interact with several medicine like: Metformin, Glimepiride, Oral contraceptives & Atorvastatin

Omariglip 12.5 Tablet: Each box contains 4X1 tablets in Alu-Alu blister pack.

Omariglip 25 Tablet: Each box contains 4X1 tablets in Alu-Alu blister pack.

Children: The safety and efficacy of this drug in children have not been established

Pregnancy: Clinical trials targeting pregnant women have not been performed so its safety cannot be predicted. Breastfeeding should be avoided.

Store below 30°C. Protect from light and moisture. keep all medicines out of the reach of children.